Patients emphasize unmet needs in opioid use disorder meeting

Participants highlighted the lack of harm-reduction strategies and non-drug opioid use disorder therapies, along with the need for medications that address more aspects of opioid use disorder including anxiety during a patient-focused drug development meeting held by FDA on Tuesday. Many respondents said that non-opiate based pain medication and non-drug pain management plans are critical for maintaining recovery.

FDA held the meeting to hear from patients, families and advocates about the effects of opioid addiction on their daily lives, their experiences with available treatment options and their unmet treatment needs...